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ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not the use of 
the drug Buprenorphine and Naloxone (Suboxone) is effective in suppressing opioid dependency 
and its withdrawal symptoms, or is it simply a surrogate for the opiate with the same addictive 
results. 
 
Study Design: Review of three primary studies in the English language published in 2010 and 
2011. 
 
Data sources: Randomized, controlled and double blind clinical trials evaluating the 
effectiveness of Suboxone in signs and symptoms of opioid withdrawal were found using the 
EBSCO Host and Lexi-Comp databases. 
 
Outcome(s) Measured: Likability of the drug versus the placebo using Visual Analog Scale 
(VAS), side effects, withdrawal symptoms using Clinical Opiate Withdrawal Scale (COWS), 
abuse potential, and drug questionnaires. 
 
Results: Three randomized controlled trials were included in this review. Suboxone was shown 
to be effective in the prevention of signs and symptoms of withdrawal. However, when 
compared to heroin participants, were significantly less willing to take low or high dose 
Suboxone again. Previous studies reported that addition of naloxone to bupornephrine reduced 
the potential of misuse. 
 
Conclusions: All three RCT proved the effectiveness of Suboxone in the management of signs 
and symptoms of opioid withdrawal with no reports of misuse. Limitations in Middleton’s study 
resulted in difficultly determining if the observed difference in abuse potential between 
intranasal buprenorphine and Suboxone was accurate with the studies done. Strain’s study 
showed that there was a significant decrease in observable withdrawal signs after administration 
of Suboxone when compared to baseline. The higher progressive ratio breakpoint for high dose 
Suboxone was similar to low dose bupornephrine in Comer’s study. This suggested that the 
naloxone component attenuated the euphoric effects of buprenorphine, resulting in decrease 
misuse potential. 
 
Key Words: Suboxone, opioid, abuse, withdrawal  
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INTRODUCTION 
 
Opioid dependency is characterized by the continued use of opioids despite significant 
opioid-induced problems. Dependency can result from the overuse of prescription drugs or from 
illicit drug use.
1
This paper encompasses three randomized controlled trials comparing 
buprenorphine/naloxone (Suboxone) effects versus placebo effects on patients going through 
drug withdrawal, while also looking at the abuse potential for Suboxone alone. Suboxone is 
known to be an effective opioid dependence pharmacotherapy, but there have been reports of 
misuse as well.
 
This topic is relevant to practice everywhere because it is a disease that a practitioner in 
any specialty will encounter.  According to the Department of Health and Human Services, 
approximately 213,000 individuals aged 12 years and older are dependent on or abuse heroin, 
and 1,707,000 individuals 12 years and older are dependent on prescription pain medications.
3 
Not only is opioid dependence or abuse extremely common, the amount of medical costs is 
astounding. In 1996, it was estimated that the total cost of heroin addiction, including medical 
costs, were $21.9 billion, while also accounting for most emergency department visits.
2
 Opioid 
dependence accounted for 66% of visits in the ED from 2004 to 2007.
3 
From 2005 to 2007, there 
was a 55% increase in ED visits for drug-related suicide attempts involving opioids; 16% of ED 
visits for drug-related suicide attempts in 2007 involved opioids.
3 
In 2000, the US Congress 
passed the Drug Addiction Treatment Act, which allows qualified physicians to treat opioid 
addiction with schedule III-V narcotics approved by the US Food and Drug Administration for 
opioid dependence treatment.
2
 This allowed for opioid treatment outside of methadone clinics, 
resulting in patients with opioid dependence history to be treated by their primary care physician. 
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Opioid dependency is a national problem and can include misuse of morphine, heroin, 
codeine, meperidine, and hydromorphine. When a patient takes these drugs they will feel an 
initial “rush” which is followed by a sense of wellbeing. Physical signs to look for in a patient 
you suspect is on opioids will be: pupillary constriction, respiratory depression, slurred speech, 
hypotension, bradycardia, and hypothermia.
4
According to the DSM criteria, dependence is 
considered when a patient has three or more of the following, occurring at any time in a 12-
month period: tolerance, withdrawal, repeated excessive use, persistent failed efforts to cut 
down, excessive time spent trying to obtain substance, reduction in important social, 
occupational, or recreational activities, and continued used despite awareness that substance is 
the cause of psychological or physical difficulties.
4
Withdrawal symptoms include: anxiety, 
pupillary dilation, diaphoresis, tachycardia, fever, diarrhea, insomnia, yawning, vomiting, 
piloerection, muscle aches, seizures, hypertension and abdominal cramps.
4 
The recommended method of treatment for opioid dependence include: methadone, 
buprenorphine, Suboxone, combined with therapy. For the purpose of this paper the focus will be 
Suboxone, which can help reduce physical withdrawal symptoms and cravings.
 
When a person 
takes an opiate, the drug attaches to mu receptors, which then releases dopamine, which results 
in pleasurable feelings.
5
 As the opioids leave the receptors, the pleasurable feelings start to fade 
away and withdrawal symptoms, such as, cravings start to occur.
5
Suboxone contains two active 
ingredients, buprenorphine and naloxone. Buprenorphine is a schedule III partial agonist at the 
mu opioid receptor that will attach to the empty opioid receptors, thus reducing the withdrawal 
symptoms.
5
There have been studies that show buprenorphine alone can have abuse liability, as it 
can produce euphoria.
4 
Naloxone is an opioid antagonist that was added to buprenorphine in 
effort to prevent the potential for intravenous misuse. Therefore, this method of treatment is 
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being proposed to see if adding naloxone to buprenorphine will decrease the incidence of misuse 
while also preventing withdrawal symptoms. 
OBJECTIVE 
The objective of this systematic review is to determine if the use of the drug Suboxone is 
effective in suppressing opioid dependency and its withdrawal symptoms, or is it simply a 
surrogate for the opiate with the same addictive results? 
METHOD 
In order to find adequate information for the research of this topic, a set of criteria was used 
for the selection of studies selected. Common interventions among all of the studies included an 
experimental group which received Suboxone or bupornephrine compared to the control group, 
which received a placebo. The comparison interventions in each of the three randomized 
controlled trials were the effects of the placebo pill versus the effects of Suboxone or 
bupornephrine while the patient was going through withdrawal. Outcomes measured in the three 
randomized control studies were the likability of the drug versus the placebo using Visual 
Analog Scale (VAS), side effects, withdrawal symptoms using Clinical Opiate Withdrawal Scale 
(COWS), and abuse potential.
2,3,5
 All studies included in this paper were randomized control 
trials obtained from EBSCO between September 2012-January 2013. Key words used in 
literature search were: “opioid dependence,” “opioid withdrawal,” “buprenorphine,” and 
“naloxone”. All articles were published in peer-reviewed journals and were written in English.  
Articles were carefully chosen based on their clinical relevance, along with following the criteria 
of being patient-oriented evidence that matters. For demographics, inclusion and exclusion 
criteria, and population refer to Table 1. Statistics reported in these studies included p-values and 
ANOVA. 
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Middleton’s study evaluated patients with opioid abuse that was confirmed by a urinalysis. 
Intervention for this study was a randomized, double blinded, 3.5 week in-patient study. On 
session days, subjects received a powder from crushed placebo, buprenorphine (2 or 8 mg) or 
Suboxone (2/0.5 or 8/2).
2
  Baseline data collected 30 minutes prior and 6 hours after drug 
administration.  
Strain’s study was a randomized control trial in which placebo versus Suboxone was studied. 
The population in this study was 74% male, average age 40 years old and 64% white.
3
The 
intervention was started by giving patients 30 mg SC morphine to develop a baseline. After day 
eight, patients were given Suboxone (4/1) at 9am, 11am, and 8pm, while another group was 
given a matching placebo.  Protocol allowed for flexible dosing for Suboxone between 12/3mg-
24/6 mg to control withdrawal symptoms.
3 
In Comer’s randomized control trial, patients were placed in a qualification phase, where 
participants who did not self-administer intravenously at least 4 mg buprenorphine more 
frequently than placebo were discontinued from the study.
6
 The next three weeks patients were 
either given a placebo, Suboxone (4/1), or buprenorphine 2mg-16mg depending on withdrawal 
symptoms.  
Table 1.Demographics & Characteristics of Included Studies. 
Study  Type #Pts 
Age 
(yrs) 
Inclusion Criteria  Exclusion Criteria  W/D Interventions  
Middleton 
(2011) 
Double 
blinded 
RCT 
12 
31 +/- 
2.27 
yrs 
31 +/- 2.27 yrs Seizure disorders 
2 
On session days, subjects 
received a powder from 
crushed placebo, 
buprenorphine (2 or 8 mg) or 
bup./naxolone (2/.5 or 8/2).   
Good health per:  
Respiratory 
disorders 
Physical exam History of asthma 
ECG (normal)  Head injury 
Medical History  HTN 
Lab tests CVD 
Baseline data collected 30 
minutes prior and 6 hours 
after drug administration  
UA confirmed illicit 
drug use 
Abnormal ECG 
  
Req. daily 
prescribed med.  
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OUTCOMES MEASURED 
 
Outcomes measured were those of patient-oriented evidence that matters. In Middleton’s 
study subjective outcomes were measured with VAS, where zero equaled “not at all” and 100 
equaled “extremely.”1 Addiction Research Center Inventory short form and street value 
questionnaire were also completed. Strains study measured primary outcomes using COWS. 
Measure of secondary outcomes included VAS, with ratings of “feeling high,” “good effects,” 
and “bad effects.”3 Participants were specifically asked to rate how the drug made them feel 
rather than how they felt in general.
3
 In Comer’s study, outcomes measured were comparing 
control versus experimental in the following areas: “drug liking,” and potential abuse using drug 
effects questionnaire, VAS, and subjective opioid withdrawal scale.
6 
RESULTS 
In Middleton’s study, using VAS, participants were asked to rate “How much do you like 
the drug?” Results showed significant dose-dependence effects (p<0.0001). Compared to the 
placebo, a significant increase in ratings of “liking” was observed 45 minutes after 
administration of Suboxone (8/2), with a Turkey test P< 0.05.
2
 However, low doses were not 
Strain 
(2011) 
RCT 38 
25 - 56 
yrs       
(μ: 
41yrs)  
18 - 65 yrs 
Patient on placebo 
with COWS   > 12 
4 
Induction of bup./naxolone 
on the first day at: 4/1 mg 
dosed at 9am, 11am, and 8 
pm for a total of 12/3 
bup./naxolone, another group 
given a matching placebo.  
DSM-IV 
(-) pregnancy 
MMSE >24 
(-) oral herpes 
No dental caries 
No recent studies  
Comer 
(2010) 
Double-
blinded 
RCT 
19 
21 - 45 
yrs 
Daily IV heroin 
Participants who did 
not self-administer 
IV 4 mg 
buprenorphine more 
frequently than 
placebo were d/c 
from the study 
7 
2 week qualification phase 
and 3 week experimental 
phase.  
Daily heroin expense: 
$30-145 
Qualification phase: 2 mg 
sublingual buprenorphine  
Duration: 2 - 32 yrs 
Experimental phase: 1
st
 
week: SL bup. stabilization 
period  
  2
nd
wk: double-blind test 
Lekas, Effectiveness of Suboxone in Opioid Dependency 6 
 
significantly different from the placebo. In table 2, peak analysis of VAS measures revealed a 
significant dose effects for “high,” “drug effect,” “like,” “good,” and “bad” (p<0.01).2 Both 
formulations produced a time and dose dependent increases on subjective effects. Patients 
reported a higher street value for buprenorphine 8 mg compared to Suboxone 8/2mg, but these 
differences were not statistically significant.
2
 Peak analyses revealed that all active doses 
differed from the placebo, with a p-value of <0.5.
2
 Based on the tests done it is difficult to 
determine if there is higher abuse potential between intranasal buprenorphine and Suboxone 
when compared to placebo.  
The incidence of adverse events occurred, but no serious side effects were noted. Table 3 
notes adverse events that presented during this study. Along with those adverse events one 
subject complained of blurred vision during the session.
2 
Table 2. Peak Scores for subjective measures (n=10) 
Subjective VAS  B/N 2/0.5: mean (SEM) B/N 8/2mg: Mean (SEM) Placebo  
Mean (SEM) 
Like 25 (6.10) 43.6 (6.10) 2.7 (1.48) 
Drug Effect 30.5 (5.62) 36.3 (5.97) 4.1 (1.86) 
High 23.1 (6.38) 35.5 (6.27) 3.3 (1.51) 
Good 24.5 (6.13) 35.5 (6.17) 3.3 (1.54) 
Bad  9.6 (3.32) 8.4 (2.83) .6 (0.50) 
 
Table 3. Safety: Adverse Events  
Side Effect Percent Affected  
Vomiting  40% 
Constipation  50% 
Headache 40% 
The Strain study measured the primary outcomes using COWS, and secondary outcomes 
using VAS. Prior to induction of the first soluble film COWS scores were elevated with a mean 
of 9.6. and after administration of Suboxone the COWS scores decreased to a mean of 5.7, which 
remained low for five days.
3
 The ratings showed that there was a significant decrease in 
observable withdrawal signs when compared to baseline. Ratings of high, bad effects, and sick 
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were measured by VAS and remained low throughout the treatment period. There were 
significant time-related variations (p<0.0001) with a peak liking of Suboxone at 51.4.
3 
Safety evaluation was conducted throughout the study. Of the 38 participants, 18 of those 
received Suboxone. Of those 18, four of the participants had mild non-ulcerous irritations of the 
oral mucosa that were not present at baseline.
3
 One patient had elevation in liver enzyme tests; 
however follow up tests showed a decline back to normal levels. Previous studies have noted that 
patients with a history of Hepatitis C whom receive buprenorphine treatment have elevated liver 
enzymes. However, no participants in this study with a history of Hepatitis C had elevated liver 
enzymes.  The results proved that the use of buprenorphine and Suboxone films to be safe and 
effective methods for opioid dependency treatment.  
Table 4.COWS Score Pre and Post Administration of B/N or Buprenorphine. 
 B/N 4/1mg  Buprenorphine  
Pre-treatment COWS score 
(mean) 
10.1 9.1 
Post-Treatment COWS score 
(mean) 
5.7 4.2 
 The randomized control study conducted by Comer included 12 participants who were 
included in the final analysis. Based on mean drug progressive ratio breakpoints, reinforcing 
effects for heroin, high dose Suboxone, low dose buprenorphine were greater when compared to 
the placebo. Low dose Suboxone demonstrated reinforcing effects lower than that for heroin 
(p=0.0001).
6
 High dose Suboxone had reinforcing effects that were also lower when compared to 
heroin (p=0.055).
6
 When individual doses were compared, participants preferred intravenous 
high dose buprenorphine over all other buprenorphine formulations. According to the Drug 
Effects Questionnaire, participants reported a higher liking for heroin, high dose Suboxone and 
low or high dose buprenorphine over the placebo (p <0.0001).
6
 For all buprenorphine 
formulations participants were willing to take the drug again when compared to the placebo, 
however, participants were significantly less willing to take low or high dose Suboxone again 
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when compared to heroin. Results of VAS showed that low dose Suboxone was the only 
formulation that differed significantly and had similar results when compared to the placebo. 
Low dose Suboxone and the placebo did not significantly differ in the following categories: good 
effects, feeling high, liking the drug, feeling sedated, and amount of money they would pay for 
the drug. Table 5 displays the results for mean subjective VAS scores, where 0 equals “not at all” 
and 100 equal “extremely.”  
 Seven adverse events were reported in participants. Adverse events that were encountered 
included: urticaria, nausea, vomiting, dizziness, and chest discomfort.
6
 Most side effects were 
mild and transient and resolved with any type of treatment. 
Table 5. Mean subjective VAS 
VAS measure  
(mean +/- SE)  
Placebo Low Dose 
Suboxone 
High Dose 
Suboxone  
Heroin  
Good effects 1.75 ± 0.90 12.67±3.07 30.61±4.20 41.11±5.24 
High 2.06±1.08 12.19±2.94 31.56±3.65 36.81±5.04 
Liked the Drug 1.19±0.62 10.50±2.44 27.28±3.97 41.56±5.42 
Would pay 0.25±0.13 1.72±0.51 5.81±0.91 8.50±1.10 
Bad effects 3.14±1.47 4.00±2.14 5.03±3.49 0.00±0.00 
 
DISCUSSION  
The three randomized controlled trials demonstrated the effectiveness of Suboxone in 
response to withdrawal symptoms. However, results also showed that patients have similar 
responses to Suboxone when compared to heroin. Although buprenorphine is believed to show 
even closer results to that of heroin, it still leaves the question as to the abuse potential for 
Suboxone.  
In Middleton’s trial, based on the current results, it is not evident that observed 
differences with regard to abuse potential between the formulations are clinically relevant at the 
doses studied.
2
 When high doses of Suboxone were compared to the placebo, participants had a 
better liking of the drugs, which leads one to believe the potential misuse. When compared to 
buprenorphine, participants had a better liking of that, which shows that by adding naloxone to 
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buprenorphine does help decrease the “high” effect. The doses used in this study were 
considered lower doses, with Suboxone doses at 2/.5 and 8/2mg.  It is noted that patients who are 
going to misuse drugs are going to do so at higher dosings.
2 
Therefore, it would have benefited 
researchers to give higher doses of Suboxone to test for abuse potential. Buprenorphine alone 
could lead to misuse via the intranasal route due to the increase in euphoric effects, along with 
the quicker onset of action.
2
Even though participants reported higher street value and drug liking 
for buprenorphine, when compared to Suboxone, the subjective ratings and street values were 
not statistically significant.
2 
Limitations noted in this study were the doses of buprenorphine and 
Suboxone along with the small sample size of ten participants. 
      The results of the clinical trials done by Strain suggest that soluble film formulations 
were effective in suppressing opioid withdrawal.
3 
Suboxone was able to attenuate signs and 
symptoms of withdrawal without belief of addiction potential due to the effects of naloxone. 
There was significant reduction in overall COWS scores, which demonstrates that the induction 
of Suboxone is effective. Suboxone was shown to be effective in reducing withdrawal signs and 
symptoms, while also having less abuse potential when compared to bupornephrine alone.
3
 A 
pervious study done, received results from a questionnaire of 145 participants in a needle 
exchange program. Of those 145 participants 8% abused Suboxone compared to the 82% who 
reported abused bupornephrine.
6 
A limitation this trial could have benefited from was having a 
longer stabilizations period using morphine, which would have strengthened the aspect of the 
study design.
5 
Another limitation to this study was in respect to the absence of precipitated 
withdrawal of symptoms and a fixed dose schedule of Suboxone. In a clinical setting a physician 
will work with the patient and adjust dosing in regards to their withdrawal symptoms. Overall the 
results of this study noted that Suboxone was effective and safe under the dose-induction period. 
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Clear advantages of soluble film formulations is that they can have the can be given as a single 
dose, in a soluble stripe form where physicians can easily track a dose of the medication.
5 
The 
rapid solubility can be an advantage in setting where monitoring administration of the 
medication is necessary.
5 
 Comer’s study identified conditions under which Suboxone had less potential to be 
abused intravenously when compared to buprenorphine or heroin.
6 
After completing the study it 
was noted that participants were willing to pay a less amount of money for Suboxone when 
compared to buprenorphine or heroin.
6
 There was a reduced administration by injection for 
participants on higher maintenance doses, which suggests that Suboxone dosing is an important 
factor in preventing misuse.
6 
If a patient is maintained on the correct dose and they are not 
experiencing withdrawal signs and symptoms they are less likely to misuse the drug.  When high 
doses of intravenous Suboxone were injected it was comparable to the effects of heroin. The 
higher progressive ratio breakpoint for high dose Suboxone was similar to low dose 
bupornephrine.
6
 This suggests that in bupornephrine dependence injection drug users, the 
naloxone component attenuated the euphoric effects of buprenorphine.
6
 This also leads 
researcher to believe that Suboxone, when compared to bupornephrine, will indeed decrease the 
misuse.
6
  The stringent criteria for enrollment and the selective population of opioid dependent 
users resulted in a small, specific population of participants, which could result in a lack of trend 
across the maintenance doses in subjective effects and might not be representative of the entire 
opioid-dependent population.
6  
 While Suboxone is commonly used across the United States for opioid dependency, there 
are limitations to its use. In regards to insurance companies, there are some physicians that will 
take any insurance and allow it to cover for the treatment of opioid dependence, while others will 
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only take cash.
5
 With that being said, most insurance companies will cover Suboxone for 
treatment of opioid dependency. The contraindications to the use of Suboxone are 
hypersensitivities to bupornephrine or naloxone.
7
 Hypersensitivity reactions that have been 
reported in the past are the following: bronchospasm, angioneurotic edema, and anaphylactic 
shock.
7
 Suboxone is a pregnancy category C and is currently not used in patients who are 
pregnant, due to the risk of neonatal withdrawal syndrome.
7
 It is also not recommended to take 
Suboxone while breastfeeding because it is not known whether naloxone is excreted in breast 
milk or not.
7
 
CONCLUSION 
 In conclusion, these studies provide evidence that Suboxone is effective in preventing 
signs and symptoms of opioid withdrawal symptoms with limited findings of misuse. In the 
United States, Suboxone is available by prescription from qualified physicians and reports of 
misuse have been limited.
6
 In Australia and Finland, the introduction of Suboxone has also been 
associated with lower rates of misuse.
6
However, in further studies that do take place, a 
recommendation that would benefit researchers would be the include a large population study 
and high doses of Suboxone. Future studies of Suboxone should include the study of sublingual 
films rather than tablets, primarily because this is what physicians are prescribing to their 
patients. In order to study the abuse potential it would be effective to monitor the same 
formulations given in the office. With any drug there is potential for misuse and abuse, 
Suboxone has been proven to have lower abuse liability when compared to what was previously 
available. The effects of naloxone have proven to be effective in blocking the effects of 
bupornephrine, ultimately reducing the risk of misuse.
4
 Close monitoring by physicians and 
practitioners, along with therapy, is imperative for success in treatment of opioid dependency. 
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